Pentasa and Pegintron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pentasa and Pegintron. Common interactions include pruritus among females and renal impairment among males.

The phase IV clinical study analyzes what interactions people who take Pentasa and Pegintron have. It is created by eHealthMe based on reports of 8 people who take Pentasa and Pegintron from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Aug, 09, 2022

8 people who take Pentasa and Pegintron together, and have interactions are studied.


What is Pentasa?

Pentasa has active ingredients of mesalamine. It is often used in crohn's disease. eHealthMe is studying from 17,561 Pentasa users for its effectiveness, alternative drugs and more.

What is Pegintron?

Pegintron has active ingredients of peginterferon alfa-2b. It is often used in hepatitis c. eHealthMe is studying from 10,307 Pegintron users for its effectiveness, alternative drugs and more.

Number of Pentasa and Pegintron reports submitted per year:

Pentasa and Pegintron drug interactions.

Common Pentasa and Pegintron drug interactions by gender *:

female:

  1. Pruritus
  2. Hyperuricaemia
  3. Rash
  4. Renal impairment
  5. Anaemia
  6. Insomnia
  7. Platelet count decreased

male:

  1. Renal impairment
  2. Ascites
  3. Hepatic encephalopathy
  4. Oedema
  5. Rash papular
  6. Rhabdomyolysis
  7. Gastric ulcer

Common Pentasa and Pegintron drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Gastric ulcer

60+:

  1. Renal impairment
  2. Anaemia
  3. Hyperuricaemia
  4. Rash
  5. Ascites
  6. Hepatic encephalopathy
  7. Oedema
  8. Rash papular
  9. Rhabdomyolysis
  10. Insomnia

* Approximation only. Some reports may have incomplete information.

Do you take Pentasa and Pegintron?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Pentasa and Pegintron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Pentasa interactions:

Browse all interactions between Pentasa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Pegintron interactions:

Browse all interactions between Pegintron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine and peginterferon alfa-2b (the active ingredients of Pentasa and Pegintron, respectively), and Pentasa and Pegintron (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: